Corient Private Wealth
UTHR icon

Corient Private Wealth’s United Therapeutics UTHR Stock Holding History

Corient Private Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.28M Sell
13,429
-7,513
-36% -$4.23M 0.01% 747
2026
Q1 		$12.4M Buy
20,942
+1,694
+9% +$844K 0.02% 540
2025
Q4 		$9.38M Buy
19,248
+2,289
+13% +$1.07M 0.01% 580
2025
Q3 		$7.11M Sell
16,959
-841
-5% -$283K 0.01% 602
2025
Q2 		$5.11M Buy
17,800
+544
+3% +$163K 0.01% 699
2025
Q1 		$5.32M Sell
17,256
-1,433
-8% -$491K 0.01% 673
2024
Q4 		$6.59M Sell
18,689
-2,041
-10% -$750K 0.01% 624
2024
Q3 		$7.43M Buy
20,730
+3,167
+18% +$1.07M 0.01% 646
2024
Q2 		$5.59M Buy
17,563
+2,776
+19% +$735K 0.01% 676
2024
Q1 		$3.4M Sell
14,787
-2,249
-13% -$508K 0.01% 812
2023
Q4 		$3.75M Buy
17,036
+461
+3% +$106K 0.01% 780
2023
Q3 		$3.74M Buy
16,575
+235
+1% +$54.1K 0.01% 709
2023
Q2 		$3.61M Buy
16,340
+8,374
+105% +$1.85M 0.01% 724
2023
Q1 		$1.78M Buy
7,966
+867
+12% +$214K ﹤0.01% 879
2022
Q4 		$1.97M Buy
+7,099
New +$1.79M 0.01% 708

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Corient Private Wealth's UTHR Position: Q2 2026 in Review

Corient Private Wealth reduced its United Therapeutics (UTHR) stake by 36% in Q2 2026, selling an estimated $4.23M and leaving 13,429 shares worth $7.28M. The position accounts for 0.01% of the portfolio, ranked #747.

Corient Private Wealth first reported a position in UTHR in Q4 2022 and has held it in 15 quarters since. The position peaked at $12.4M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Corient Private Wealth held 13,429 shares of United Therapeutics worth $7.28M as of Q2 2026.
  • Corient Private Wealth sold 7,513 United Therapeutics shares in Q2 2026, an estimated $4.23M.
  • United Therapeutics made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #747 holding.
  • Corient Private Wealth first reported a position in United Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's United Therapeutics position peaked at $12.4M in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.